The Overlap between Headache and Epilepsy in the Light of Recent Advances in Medical Genetics

Not Available

FGF2 is expressed in human and murine embryonic choroid plexus and affects choroid plexus cell behaviour

<p>Abstract</p> <p>Background</p> <p>Although fibroblast growth factor (Fgf) signalling plays crucial roles in several developing and mature tissues, little information is currently available on expression of Fgf2 during early choroid plexus development and whether Fgf2 directly affects the behaviour of the choroid plexus epithelium (CPe). The purpose of this study was to investigate expression of Fgf2 in rodent and human developing CPe and possible function of Fgf2, using <it>in vitro </it>models. The application of Fgf2 to brain <it>in vivo </it>can affect the whole tissue, making it difficult to assess specific responses of the CPe.</p> <p>Methods</p> <p>Expression of Fgf2 was studied by immunohistochemistry in rodent and human embryonic choroid plexus. Effects of Fgf2 on growth, secretion, aggregation and gene expression was investigated using rodent CPe vesicles, a three-dimensional polarized culture model that closely mimics CPe properties <it>in vivo</it>, and rodent CPe monolayer cultures.</p> <p>Results</p> <p>Fgf2 was present early in development of the choroid plexus both in mouse and human, suggesting the importance of this ligand in Fgf signalling in the developing choroid plexus. Parallel analysis of Fgf2 expression and cell proliferation during CP development suggests that Fgf2 is not involved in CPe proliferation <it>in vivo</it>. Consistent with this observation is the failure of Fgf2 to increase proliferation in the tri-dimensional vesicle culture model. The CPe however, can respond to Fgf2 treatment, as the diameter of CPe vesicles is significantly increased by treatment with this growth factor. We show that this is due to an increase in cell aggregation during vesicle formation rather than increased secretion into the vesicle lumen. Finally, Fgf2 regulates expression of the CPe-associated transcription factors, <it>Foxj1 </it>and <it>E2f5</it>, whereas transthyretin, a marker of secretory activity, is not affected by Fgf2 treatment.</p> <p>Conclusion</p> <p>Fgf2 expression early in the development of both human and rodent choroid plexus, and its ability to modulate behaviour and gene expression in CPe, supports the view that Fgf signalling plays a role in the maintenance of integrity and function of this specialized epithelium, and that this role is conserved between rodents and humans.</p

The upgrade of the RPC-based ALICE Muon Trigger

The ALICE Muon Trigger is currently yielded by a detector currently composed of 72 Bakelite single-gap Resistive Plate Chambers operated in maxi-avalanche mode, arranged in four 5.5x6.5 m2 detection planes. In order to meet the requirements posed by the forthcoming LHC high luminosity runs starting from 2021 onwards, in which ALICE will be read out in continuous mode, the Muon Trigger will become a Muon Identifier and will undergo a major upgrade. In the current setup, signals from about 21k strips are discriminated by 2400 non-amplified Front End (FEE) cards, whose thresholds are provided by external analog voltages (one for each chamber side). All these cards will be replaced with discriminators equipped with a pre-amplification stage which will allow a reduction in the operating high voltage of the detectors, thus prolonging their lifetime. Furthermore, their reference thresholds will be passed via wireless (and I2C chained per chamber side) allowing the tuning of the values at the single card level. Moreover, the 24 most exposed chambers will be replaced with new ones, equipped with high-quality (i.e. smoother surface) Bakelite laminates. The tests performed on the new FEE cards, used both in a test bench and on detectors, and on the new RPC chambers (with cosmic rays) are reported.Comment: Proceeding of the 14th Workshop on Resistive Plate Chambers and Related Detectors 19-23 February 2018 Puerto Vallarta, Jalisco State, Mexic

A survey of cherry leaf roll virus in intensively managed grafted english (Persian) walnut trees in Italy

Blackline disease, caused by Cherry leaf roll virus (CLRV), is considered a serious threat limiting English walnut (Juglans regia) production in Italy and the EU if walnut species other than J. regia e.g. \u2018Paradox\u2019 hybrid (J. regia 7 J. hindsii), French hybrid (J. regia 7 J. major or J. regia 7 J. nigra) or northern California black walnut (J. hindsii) are used as the rootstock. The virus transmissibility by pollen as well as latent infections can result in the spread of CLRVcontaminated propagative material, which is a major means of the virus dispersal by human activities. In 2014 and 2015 to ascertain the presence and the distribution of blackline symptoms in commercial orchards and to provide a description of the symptomatology, visual inspections and double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) analyses were carried out on 1,684 walnut trees in four different intensively managed grafted English walnut orchards in northeast Italy (Veneto Region). Trees with clear blackline symptoms at the scion-rootstock junction, often associated with general decline of the plant, were found only in one commercial orchard in northeast Italy on trees older than ten years of cvs. \u2018Tulare\u2019 and \u2018Chandler\u2019, grafted onto \u2018Paradox\u2019 rootstock. To our knowledge this is the first report of CLRV (blackline) decline and death in a commercial walnut orchard in Italy

Impressive long-term response with pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastasis

This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months